噻托溴铵联合沙美特罗替卡松治疗慢性阻塞性肺疾病的临床效果

Clinical efficacy of tiotropium bromide combined with salmeterol fluticasone propionate in treatment of chronic obstructive pulmonary disease

目的探讨噻托溴铵联合沙美特罗替卡松治疗慢性阻塞性肺疾病的临床效果。方法选择88例患者,随机分为两组,各44例,观察组使用噻托溴铵联合沙美特罗替卡松治疗,对照组单纯使用噻托溴铵治疗,比较治疗后2周患者肺功能,并比较上午10:00测定的患者生活活动能力(ADL)评分和6min步行距离。结果观察组治疗后1周FEV1和FVC均显著大于对照组(P<0.05),FEV1/FVC和FEV1占预计值则显著高于对照组(P<0.05),生活活动能力评分显著高于对照组(P<0.05),且6min步行距离显著长于对照组(P<0.05)。结论噻托溴铵联合沙美特罗替卡松治疗COPD,能加快改善患者肺功能,且提高患者生活质量,值得临床推广。

Objective To investigate the effect of tiotropium bromide combined with salmeterol fluticasone propionate for chronic obstructive pulmonary disease. Methods Eighty-eight cases of patients were randomly divided into two groups, the observation group （44 cases） were used tiotropium bromide combined with salmeterol fluticasone propi- onate, the control group （44 cases） were used only tiotropium bromide, after 2 weeks the pulmonary function, activities of daily living （ADL） and the score of 6 rain walk distance were compared. Results The observation group with FEV1 and FVC were higher than control group （P 〈 0.05）, FEV1/FVC and FEV1 percentage were higher than control group （P 〈 0.05）, activities of daily living score was higher than control group （P 〈 0.05）, and 6 min walking distance was longer than control group （P 〈 0.05）. Conclusion Tiotropium bromide combined with combined with salmeterol fluticasone propionate for chronic obstructive pulmonary disease can accelerate the improvement of pulmonary function and im- prove patients＇ life quality, so it is worthy of clinical application.